Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
-
IGM Financial, a Member of the Power Corporation Group of Companies, Making Long-Term Strategic Investment in Rockefeller Capital Management; Becomes Shareholder Alongside Majority Investor Viking Glo
-
Cazoo Announces Fourth Quarter and Full Year 2022 Financial Results
-
Pragma Bio Secures $10M From The Venture Collective, Merck Global Health Innovation Fund, Viking Global, and CJ Investments To Expand Its Proprietary Technology Platform To Discover Novel Medicines
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Cazoo to Announce Full-Year and Fourth Quarter 2022 Results on March 30, 2023
-
CNM LLP Appoints Bill Strong as President to Lead Global Business Operations and Strategic Growth
-
Cazoo (CZOO) Provides Year-to-Date Business Performance Update
-
Cazoo Provides Year-to-Date Business Performance Update
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Cazoo (CZOO) Sells Cazana Data Platform
-
Cazoo Sells Cazana Data Platform
-
Cazoo (CZOO) Agrees Sale of German Subscription Business
-
Cazoo Agrees Sale of German Subscription Business
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31
-
Form SC 13G/A FIGS, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Inhibrx, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Amylyx Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Guardant Health, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Pharvaris N.V. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PROCEPT BioRobotics Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Orion Acquisition Corp. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Edgewise Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Coupa Software Inc Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Celldex Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
-
Cazoo (CZOO) Announces Reverse Stock Split and Increase in Authorized Share Capital
-
Cazoo Announces Reverse Stock Split and Increase in Authorized Share Capital
-
Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck
-
Pearl Health raises $75M Series B led by a16z to accelerate growth and innovation in value-based care
-
Top hedge funds earned sharply less for clients in 2022, LCH data shows
-
SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases
-
Cazoo (CZOO) Reports Prelim Q4 Results, Revises 2023 Guidance
-
Cazoo Announces Fourth Quarter 2022 Preliminary Financial Results and Revised 2023 Plan
-
Battelle, Viking Global Investors Launch Revive Environmental™
-
Form D/A Viking Global Opportunit
-
Form D/A Viking Global Opportunit
-
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
-
Mantra Bio Raises $9 Million in Series A-2 Financing to Advance Development of Lead Targeted Exosome Therapeutics Program
-
Tourmaline Partners Adds Industry Veteran Matt Ney to Trading Team
-
Patina announces partnerships with major national Medicare Advantage plans, significantly expanding the reach of its unique primary care experience for adults 65+ in Philadelphia region
-
Cazoo (CZOO) Sells Its Spanish Subscription Business
-
Cazoo Sells Its Spanish Subscription Business
